Status and phase
Conditions
Treatments
About
The purpose of this study is to determine if Dymista nasal spray is better and safer than placebo in treating children ages 4 to <12 years old who have seasonal allergic rhinitis.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
At Visit 2:
Have taken at least 6 doses of the placebo lead-in medication during the placebo lead-in period
At Visit 2, to be eligible for entry into the double-blind treatment period, subjects must have the total of the seven lead-in symptom assessments during the past 3 days of the lead-in period including the Day of Randomization (Visit 2, Day 1):
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
348 participants in 2 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal